Find out more about the overall breast cancer treatment landscape, as biotech companies make progress with different ...

A company presentation will take place during the conference’s Innovation track on Friday, March 28th at 9:00am. NeauxCancer conference’s Innovation track spotlights the most promising emerging ...

Delytact (teserpaturev) is a genetically engineered oncolytic herpes simplex virus type 1 (HSV-1) that was approved for marketing in Japan earlier this year, and received pricing approval in ...

在抗击癌症这一人类健康的“头号杀手”之战中，武汉博威德生物技术有限公司的最新成果令人振奋。2025年2月26日，博威德生物研发的抗肿瘤创新药重组柯萨奇病毒B3注射液，商标名“爱速可”，成功获得美国食品药品监督管理局（FDA）的临床试验批准，标志着对付恶性肿瘤的治疗手段又添一把利器。

ELIAS Animal Health, a leading companion animal cancer therapeutics company, today announced its adoptive cell therapy, ELIAS Cancer Immunotherapy (ECI®), has received full approval from the U.S.

It's not the first therapy in the oncolytic virus class to be approved around the world, as that accolade went to Amgen's Imlygic (talimogene laherparepvec), which was cleared by the FDA for the ...

RedChip Companies will air interviews with Nexalin Technology, Inc. (Nasdaq:NXL) and Calidi Biotherapeutics, Inc. (NYSE American:CLDI) on the RedChip Small Stocks, Big Money™ show, a sponsored program ...

Detailed price information for Candel Therapeutics Inc (CADL-Q) from The Globe and Mail including charting and trades.

溶瘤细菌的作用机制独特而精妙。当它们定位到肿瘤微环境后，不仅能够特异性地在肿瘤内部大量繁殖，诱导肿瘤细胞死亡，还能充当载体，递送药物及免疫刺激分子，从多个维度对抗肿瘤。那接下来，就让我们以全球首创的溶瘤细菌载体产品—— 上海缮维特生物技术有限公司研发 ...

CG Oncology (NASDAQ:CGON – Get Free Report) is projected to post its quarterly earnings results before the market opens on Tuesday, March 25th. Analysts expect CG Oncology to post earnings of ($0.37) ...

After hours: March 17 at 5:57:57 PM EDT Loading Chart for MBIO ...